Serial analysis of CTL responses in 8 patients treated with repeated cycles of AZA/VPA therapy. The frequency of the CTA-specific CTL response has been calculated from the pre-enrichment estimate by subtracting the percentage of T cells detected in the unstimulated analysis (see “Detection and quantification of MAGE-reactive T cells in patients with AML and MDS treated with AZA/VPA”). The x-axis illustrates the number of days after treatment, and the y-axis shows the frequency of CTA-specific CTL response. CTAg indicates cancer testis antigen.